Literature DB >> 14527307

Enzyme therapy for lysosomal storage disease: principles, practice, and prospects.

Gregory A Grabowski1, Robert J Hopkin.   

Abstract

Over the past three decades, enzyme therapy for lysosomal storage diseases has moved from an academic pursuit to direct delivery of effective clinical care for affected patients and families. This success is based on understanding the complexities of lysosomal biogenesis, lysosomal hydrolase sorting and hydrolytic requirements, and the target sites of pathology of these diseases. This article reviews these concepts and their application to the treatment of affected patients with Gaucher disease, Fabry disease, and mucopolysaccharidosis I. The principles, progress, and practice in these diseases provide prototypes for expansion of enzyme therapy to a growing set of these diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14527307     DOI: 10.1146/annurev.genom.4.070802.110415

Source DB:  PubMed          Journal:  Annu Rev Genomics Hum Genet        ISSN: 1527-8204            Impact factor:   8.929


  31 in total

1.  Targeting of lysosomes by liposomes modified with octadecyl-rhodamine B.

Authors:  Alexander Koshkaryev; Ritesh Thekkedath; Cinzia Pagano; Igor Meerovich; Vladimir P Torchilin
Journal:  J Drug Target       Date:  2011-01-29       Impact factor: 5.121

2.  Bilateral symmetrical cortical osteolytic lesions in two patients with Gaucher disease.

Authors:  Ian M Oppenheim; Astrid Medina Canon; William Barcenas; Catherine Groden; Ozlem Goker-Alpan; Charles S Resnik; Ellen Sidransky
Journal:  Skeletal Radiol       Date:  2011-09-20       Impact factor: 2.199

3.  Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening.

Authors:  Yijun Li; C Ronald Scott; Nestor A Chamoles; Ahmad Ghavami; B Mario Pinto; Frantisek Turecek; Michael H Gelb
Journal:  Clin Chem       Date:  2004-08-03       Impact factor: 8.327

4.  Molecular basis of reduced glucosylceramidase activity in the most common Gaucher disease mutant, N370S.

Authors:  Marc N Offman; Marcin Krol; Israel Silman; Joel L Sussman; Anthony H Futerman
Journal:  J Biol Chem       Date:  2010-10-27       Impact factor: 5.157

5.  A breach in the blood-brain barrier.

Authors:  Jonathan H Lebowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

6.  A survey of the pain experienced by males and females with Fabry disease.

Authors:  Andrea L Gibas; Regan Klatt; Jack Johnson; Joe T R Clarke; Joel Katz
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

Review 7.  Clinical neurogenetics: neuropathic lysosomal storage disorders.

Authors:  Gregory M Pastores; Gustavo H B Maegawa
Journal:  Neurol Clin       Date:  2013-11       Impact factor: 3.806

Review 8.  Subcellular targeting strategies for drug design and delivery.

Authors:  Lawrence Rajendran; Hans-Joachim Knölker; Kai Simons
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

Review 9.  Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  BioDrugs       Date:  2010-02-01       Impact factor: 5.807

10.  Characterization and application of a disease-cell model for a neurodegenerative lysosomal disease.

Authors:  Jameson J Ribbens; Ann B Moser; Walter C Hubbard; Ernesto R Bongarzone; Gustavo H B Maegawa
Journal:  Mol Genet Metab       Date:  2013-09-21       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.